Staying Current With Apps
Retina specialists are finding that apps are not just for music and games anymore.
RISC and Reward with Inhibitory RNAs
A new understanding of ribonucleic acid’s activity in cells may
lead to breakthroughs in ophthalmic treatment.
Speaking With Patients About Premium IOL Clinical Trials
Section Editor Ryan Bouchard interviews John Berdahl, MD.
Delivering a Rocky Mountain ARVO
A rundown of the most interesting research in a variety of subspecialties presented at this year’s ARVO meeting.
Ocular Therapeutix™ Begins Enrollment in Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Allergic Conjunctivitis
Phase 3 Allergy Program Establishes Clinical Indication Expansion Strategy of DEXTENZA™
The Secrets of Ocular Microbiomes
The placid ocular surface is actually teeming with life that might
hold the secret to treating ophthalmic disease.
Advances in pharmacotherapy for allergic conjunctivitis
Allergic conjunctivitis is a common and potentially debilitating condition affecting
the conjunctiva, eyelids and cornea, and it is often associated with nonocular symptoms
and signs of rhinitis or sinusitis.
Another great year at ARVO.
See you next year in Seattle!
Portola Pharmaceuticals Announces Collaboration With Ora, Inc. for Syk-selective Inhibitor (PRT2761) in Ophthalmic Diseases
Collaboration Allows Portola to Advance Product Candidates Outside of Core Focus
Avoiding Protocol Deviations In Clinical Research
Deviations should be rare. The protocol helps
to keep the study on track.